Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.34 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14567629 | 0.82 | TSHR (0.37) | TSHRANPEPENPEPLMNACA2 | |
| SCHEMBL14969740 | 0.81 | RNPEP (0.33) | ANPEPENPEPRNPEPLMNAMEN1 | |
| SCHEMBL3262043 | 0.81 | RNPEP (0.33) | ANPEPENPEPRNPEPLMNAMEN1 | |
| SCHEMBL4572445 | 0.81 | RNPEP (0.38) | ANPEPRNPEPLMNACA2CA1 | |
| SCHEMBL10172364 | 0.80 | — | — | |
| SCHEMBL16230377 | 0.80 | ANPEP (0.36) | TSHRANPEPENPEPRNPEPLMNA | |
| SCHEMBL11130899 | 0.79 | TSHR (0.41) | TSHRRNPEPLMNACA2CA1 | |
| SCHEMBL10287235 | 0.79 | RNPEP (0.32) | ANPEPENPEPRNPEPLMNA | |
| SCHEMBL13347807 | 0.79 | RNPEP (0.36) | ANPEPENPEPRNPEPLMNA | |
| SCHEMBL7288159 | 0.79 | TSHR (0.41) | TSHRRNPEPLMNACA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1912932-B1 | INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-A MODULATORS; SYNTHESES OF SUCH MODULATORS AND METHODS OF USING SUCH MODULATORS | NEREUS PHARMACEUTICALS INC (US) | 2012-05-02 | — | — | EP | disclosed |
| EP-2311795-A2 | Interleukin-1 and tumor necrosis factor-alpha modulators; syntheses of such modulators and methods of using such modulators | Nereus Pharmaceuticals, Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| US-7893233-B2 | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays | CORNELL RESEARCH FOUNDATION, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20100173802-A1 | DETECTION OF NUCLEIC ACID SEQUENCE DIFFERENCES USING THE LIGASE DETECTION REACTION WITH ADDRESSABLE ARRAYS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| EP-1607606-B1 | Method and device for determining an internal combustion engine intake air flow rate based on the measurement of the oxygen concentration in the gaseous mixture taken in by the engine | FIAT RICERCHE (IT) | 2008-04-09 | — | — | EP | disclosed |
| US-20080064753-A1 | Interleukin-1 and tumor necrosis factor-alpha modulators; syntheses of such modulators and methods of using such modulators | HENSLER, MARY | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064753-A1 | Interleukin-1 and tumor necrosis factor-alpha modulators; syntheses of such modulators and methods of using such modulators | IL1A, IL1B, TNF | TSHR 1529/4885ANPEP 1436/4885ENPEP 2477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.